Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.50

-1.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: celeryroot.com who wrote (28675)	4/13/1999 8:54:00 AM
From: Mudcat	Read Replies (2) of 32384

A section from the article for the AACR presentation states: "Ligand has also studied Targretin for the treatment of patients with cutaneous T-cell lymphoma, for which Ligand expects to file a new drug application for Targretin capsules in the first half of 1999, as well as advanced lung cancer, ovarian cancer, head and neck cancer, Kaposi's sarcoma, psoriasis and actinic keratoses." Does this statement imply that treatment with Targretin was ineffective for advanced lung cancer, ovarian cancer, head and neck cancer, Kaposi's sarcoma, psoriasis and actinic keratoses, since LGND only expects to file an NDA for cutaneous T-Cell lymphoma?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next